AI and New Imaging Tools Reshape Breast Cancer Detection

Artificial intelligence and a new generation of imaging tools are beginning to reshape breast cancer detection, moving the field toward earlier identification and more personalized screening recommendations. About one in eight women will develop breast cancer in their lifetime, but the five-year survival rate reaches 90% to 100% when caught early, making detection advances among the most consequential developments in the field.

As these advances in breast cancer diagnosis become commonplace, a lot more women could benefit from the cutting-edge treatment approaches being developed by several companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI). The news release, distributed by TinyGems, highlights the latest testing and screening advances in breast cancer treatment and features Calidi Biotherapeutics as an innovative small-cap company with bright futures and huge potential in the oncology space. The article is part of TinyGems' specialized communications platform that focuses on innovative small-cap and mid-cap companies.

TinyGems is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.